aBLA Filing Intelligence & Biosimilar Opportunity

Rybrevant

Amivantamab-Vmjw

Anticancer

Injection Injectable

Approval Date

21-May-21

Data Exclusivity Expiry

21-May-25

Market Exclusivity Expiry

21-May-33

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

108

2027

183

2028

247

2029

287

2030

324

2031

353

2032

374

Molecule profile

Details & specifications

Molecule

Amivantamab-Vmjw

Innovator

JANSSEN BIOTECH, INC.

Dosage Form

Injection Injectable

Strength

350 mg/7 mL (50 mg/mL)

Therapeutic Category

Anticancer

Usage

To treat a subset of non-small cell lung cancer

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.